Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 12
2021 56
2022 45
Text availability
Article attribute
Article type
Publication date

Search Results

100 results
Results by year
Filters applied: . Clear all
Page 1
Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC).
van Akkooi ACJ, Hieken TJ, Burton EM, Ariyan C, Ascierto PA, Asero SVMA, Blank CU, Block MS, Boland GM, Caraco C, Chng S, Davidson BS, Duprat Neto JP, Faries MB, Gershenwald JE, Grunhagen DJ, Gyorki DE, Han D, Hayes AJ, van Houdt WJ, Karakousis GC, Klop WMC, Long GV, Lowe MC, Menzies AM, Olofsson Bagge R, Pennington TE, Rutkowski P, Saw RPM, Scolyer RA, Shannon KF, Sondak VK, Tawbi H, Testori AAE, Tetzlaff MT, Thompson JF, Zager JS, Zuur CL, Wargo JA, Spillane AJ, Ross MI; International Neoadjuvant Melanoma Consortium (INMC). van Akkooi ACJ, et al. Ann Surg Oncol. 2022 Jun;29(6):3694-3708. doi: 10.1245/s10434-021-11236-y. Epub 2022 Jan 28. Ann Surg Oncol. 2022. PMID: 35089452
Assessment of the management of carcinomatous meningitis from breast cancer globally: a study by the Breast International Group Brain Metastasis Task Force.
Razis E, Escudero MJ, Palmieri C, Mueller V, Bartsch R, Rossi G, Gampenrieder SP, Kolberg HC, Zdenkowski N, Pavic M, Connolly RM, Rosset L, Arcuri J, Tesch H, Vallejos C, Retamales J, Musolino A, Del Mastro L, Christodoulou C, Aebi S, Paluch-Shimon S, Gupta S, Ohno S, Macpherson I, Ekholm M, Zaman K, Vidal M, Chakiba C, Fumagalli D, Thulin A, Witzel I, Kotecki N, Gil-Gil M, Linderholm B. Razis E, et al. ESMO Open. 2022 May 13;7(3):100483. doi: 10.1016/j.esmoop.2022.100483. Online ahead of print. ESMO Open. 2022. PMID: 35576695 Free article.
As many as 20 centers have a national registry for patients with breast cancer with central nervous system metastases and of those 5 have one for CM. Most (90.9%) centers would be interested in participating in a registry as well as in studies for CM, the latter preferably …
As many as 20 centers have a national registry for patients with breast cancer with central nervous system metastases and of those 5 …
5-fluorouracil treatment of patient-derived scaffolds from colorectal cancer reveal clinically critical information.
Salerno S, Ståhlberg A, Holdfeldt A, Bexe Lindskog E, Landberg G. Salerno S, et al. J Transl Med. 2022 May 13;20(1):209. doi: 10.1186/s12967-022-03423-6. J Transl Med. 2022. PMID: 35562738 Free PMC article.
BACKGROUND: Colorectal cancer is a commonly diagnosed cancer worldwide. Unfortunately, many patients do not respond to standard chemotherapy treatments and develop disease relapse and metastases. ...By using a recently developed patient-derived scaffold method monit …
BACKGROUND: Colorectal cancer is a commonly diagnosed cancer worldwide. Unfortunately, many patients do not respond to standar …
Deficiency of SARS-CoV-2 T-cell responses after vaccination in long-term allo-HSCT survivors translates into abated humoral immunity.
Einarsdottir S, Martner A, Waldenström J, Nicklasson M, Ringlander J, Arabpour M, Törnell A, Wiktorin HG, Nilsson S, Bittar R, Nilsson M, Lisak M, Veje M, Friman V, Al-Dury S, Bergström T, Ljungman P, Brune M, Hellstrand K, Lagging M. Einarsdottir S, et al. Blood Adv. 2022 May 10;6(9):2723-2730. doi: 10.1182/bloodadvances.2021006937. Blood Adv. 2022. PMID: 35286374 Free PMC article.
PAM50 subtyping and ROR score add long-term prognostic information in premenopausal breast cancer patients.
Lundgren C, Bendahl PO, Church SE, Ekholm M, Fernö M, Forsare C, Krüger U, Nordenskjöld B, Stål O, Rydén L. Lundgren C, et al. NPJ Breast Cancer. 2022 May 9;8(1):61. doi: 10.1038/s41523-022-00423-z. NPJ Breast Cancer. 2022. PMID: 35534504 Free PMC article.
We aimed to examine their long-term prognostic value in terms of breast cancer-free interval (BCFi) and overall survival (OS) (n = 437) in premenopausal women randomised to 2 years of tamoxifen versus no systemic treatment irrespective of hormone-receptor status. ...These …
We aimed to examine their long-term prognostic value in terms of breast cancer-free interval (BCFi) and overall survival (OS) (n = 43 …
Early intestinal microbial features are associated with CD4 T-cell recovery after allogeneic hematopoietic transplant.
Miltiadous O, Waters NR, Andrlová H, Dai A, Nguyen CL, Burgos da Silva M, Lindner S, Slingerland J, Giardina P, Clurman A, Armijo GK, Gomes ALC, Lakkaraja M, Maslak P, Scordo M, Shouval R, Staffas A, O'Reilly R, Taur Y, Prockop S, Boelens JJ, Giralt S, Perales MA, Devlin SM, Peled JU, Markey KA, van den Brink MRM. Miltiadous O, et al. Blood. 2022 May 5;139(18):2758-2769. doi: 10.1182/blood.2021014255. Blood. 2022. PMID: 35061893
The synthetic triterpenoids CDDO-TFEA and CDDO-Me, but not CDDO, promote nuclear exclusion of BACH1 impairing its activity.
Casares L, Moreno R, Ali KX, Higgins M, Dayalan Naidu S, Neill G, Cassin L, Kiib AE, Svenningsen EB, Minassi A, Honda T, Poulsen TB, Wiel C, Sayin VI, Dinkova-Kostova AT, Olagnier D, de la Vega L. Casares L, et al. Redox Biol. 2022 May;51:102291. doi: 10.1016/j.redox.2022.102291. Epub 2022 Mar 17. Redox Biol. 2022. PMID: 35313207 Free PMC article.
The transcription factor BACH1 is a potential therapeutic target for a variety of chronic conditions linked to oxidative stress and inflammation, as well as cancer metastasis. However, only a few BACH1 degraders/inhibitors have been described. ...Notably, we demonstrate th …
The transcription factor BACH1 is a potential therapeutic target for a variety of chronic conditions linked to oxidative stress and inflamma …
Development of head and neck pathology in Europe.
Hellquist H, Agaimy A, Stenman G, Franchi A, Nadal A, Skalova A, Leivo I, Zidar N, Simpson RHW, Slootweg PJ, Hernandez-Prera JC, Ferlito A. Hellquist H, et al. Virchows Arch. 2022 May;480(5):951-965. doi: 10.1007/s00428-022-03275-x. Epub 2022 Jan 14. Virchows Arch. 2022. PMID: 35028711 Review.
During the last three decades, the use of immunohistochemistry supplemented with cytogenetic and refined molecular techniques has greatly facilitated the pathological diagnostics of head and neck lesions and has had a huge impact on research. Collaboration between differen …
During the last three decades, the use of immunohistochemistry supplemented with cytogenetic and refined molecular techniques has greatly fa …
Recurrent copy number alterations involving EGFR, CDKN2A, and CCND1 in oral premalignant lesions.
Jäwert F, Fehr A, Öhman J, Stenman G, Kjeller G. Jäwert F, et al. J Oral Pathol Med. 2022 Apr 30. doi: 10.1111/jop.13303. Online ahead of print. J Oral Pathol Med. 2022. PMID: 35488777
METHODS: Using a novel, custom-made tissue microarray including 28 high-risk oral leukoplakias and the corresponding oral squamous cell carcinomas from 14 cases that progressed to cancer, we assayed copy number alterations involving the oral squamous cell carcinoma driver …
METHODS: Using a novel, custom-made tissue microarray including 28 high-risk oral leukoplakias and the corresponding oral squamous cell carc …
Breast Cancer Patient-Derived Scaffolds Can Expose Unique Individual Cancer Progressing Properties of the Cancer Microenvironment Associated with Clinical Characteristics.
Garre E, Gustafsson A, Leiva MC, Håkansson J, Ståhlberg A, Kovács A, Landberg G. Garre E, et al. Cancers (Basel). 2022 Apr 26;14(9):2172. doi: 10.3390/cancers14092172. Cancers (Basel). 2022. PMID: 35565301 Free PMC article.
Breast cancer is a heterogeneous disease in terms of cellular and structural composition, and besides acquired aggressive properties in the cancer cell population, the surrounding tumor microenvironment can affect disease progression and clinical behaviours. ...The …
Breast cancer is a heterogeneous disease in terms of cellular and structural composition, and besides acquired aggressive properties …
A somatic mutation in moesin drives progression into acute myeloid leukemia.
Yuan O, Ugale A, de Marchi T, Anthonydhason V, Konturek-Ciesla A, Wan H, Eldeeb M, Drabe C, Jassinskaja M, Hansson J, Hidalgo I, Velasco-Hernandez T, Cammenga J, Magee JA, Niméus E, Bryder D. Yuan O, et al. Sci Adv. 2022 Apr 22;8(16):eabm9987. doi: 10.1126/sciadv.abm9987. Epub 2022 Apr 20. Sci Adv. 2022. PMID: 35442741 Free PMC article.
Upon clonal transformation, we identified and extensively verified a recurrent codon-changing mutation (Arg(295)Cys) in the ERM protein moesin that markedly accelerated leukemogenesis. Human cancer-associated moesin mutations at the conserved arginine-295 residue similarly …
Upon clonal transformation, we identified and extensively verified a recurrent codon-changing mutation (Arg(295)Cys) in the ERM protein moes …
KRAS Mutations Impact Clinical Outcome in Metastatic Non-Small Cell Lung Cancer.
Eklund EA, Wiel C, Fagman H, Akyürek LM, Raghavan S, Nyman J, Hallqvist A, Sayin VI. Eklund EA, et al. Cancers (Basel). 2022 Apr 20;14(9):2063. doi: 10.3390/cancers14092063. Cancers (Basel). 2022. PMID: 35565194 Free PMC article.
Here, we evaluated whether treatment outcome could be affected by KRAS mutational status in patients with metastatic (Stage IV) non-small cell lung cancer (NSCLC). All consecutive patients molecularly assessed and diagnosed between 2016-2018 with Stage IV NSCLC in the regi …
Here, we evaluated whether treatment outcome could be affected by KRAS mutational status in patients with metastatic (Stage IV) non-small ce …
Correction to: Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC).
van Akkooi ACJ, Hieken TJ, Burton EM, Ariyan C, Ascierto PA, Asero SVMA, Blank CU, Block MS, Boland GM, Caraco C, Chng S, Davidson BS, Duprat Neto JP, Faries MB, Gershenwald JE, Grunhagen DJ, Gyorki DE, Han D, Hayes AJ, van Houdt WJ, Karakousis GC, Klop WMC, Long GV, Lowe MC, Menzies AM, Bagge RO, Pennington TE, Rutkowski P, Saw RPM, Scolyer RA, Shannon KF, Sondak VK, Tawbi H, Testori AAE, Tetzlaff MT, Thompson JF, Zager JS, Zuur CL, Wargo JA, Spillane AJ, Ross MI; International Neoadjuvant Melanoma Consortium (INMC). van Akkooi ACJ, et al. Ann Surg Oncol. 2022 Apr 15. doi: 10.1245/s10434-022-11622-0. Online ahead of print. Ann Surg Oncol. 2022. PMID: 35426590 No abstract available.
Endoscopic ultrasound-guided side-fenestrated needle biopsy sampling is sensitive for pancreatic neuroendocrine tumors but inadequate for tumor grading: a prospective study.
Appelstrand A, Bergstedt F, Elf AK, Fagman H, Hedenström P. Appelstrand A, et al. Sci Rep. 2022 Apr 8;12(1):5971. doi: 10.1038/s41598-022-09923-1. Sci Rep. 2022. PMID: 35396490 Free PMC article.
We aimed to evaluate endoscopic ultrasound-guided fine needle biopsy sampling (EUS-FNB) for the preoperative diagnosis and grading of PanNETs. In a tertiary-center setting, patients with suspected PanNETs were prospectively subjected to 22-gauge, reverse-bevel EUS-FNB. ...
We aimed to evaluate endoscopic ultrasound-guided fine needle biopsy sampling (EUS-FNB) for the preoperative diagnosis and grading of PanNET …
Validated biomarker assays confirm that ARID1A loss is confounded with MMR deficiency, CD8+ TIL infiltration, and provides no independent prognostic value in endometriosis-associated ovarian carcinomas.
Heinze K, Nazeran TM, Lee S, Krämer P, Cairns ES, Chiu DS, Leung SC, Kang EY, Meagher NS, Kennedy CJ, Boros J, Kommoss F, Vollert HW, Heitz F, du Bois A, Harter P, Grube M, Kraemer B, Staebler A, Kommoss FK, Heublein S, Sinn HP, Singh N, Laslavic A, Elishaev E, Olawaiye A, Moysich K, Modugno F, Sharma R, Brand AH, Harnett PR, DeFazio A, Fortner RT, Lubinski J, Lener M, Tołoczko-Grabarek A, Cybulski C, Gronwald H, Gronwald J, Coulson P, El-Bahrawy MA, Jones ME, Schoemaker MJ, Swerdlow AJ, Gorringe KL, Campbell I, Cook L, Gayther SA, Carney ME, Shvetsov YB, Hernandez BY, Wilkens LR, Goodman MT, Mateoiu C, Linder A, Sundfeldt K, Kelemen LE, Gentry-Maharaj A, Widschwendter M, Menon U, Bolton KL, Alsop J, Shah M, Jimenez-Linan M, Pharoah PD, Brenton JD, Cushing-Haugen KL, Harris HR, Doherty JA, Gilks B, Ghatage P, Huntsman DG, Nelson GS, Tinker AV, Lee CH, Goode EL, Nelson BH, Ramus SJ, Kommoss S, Talhouk A, Köbel M, Anglesio MS. Heinze K, et al. J Pathol. 2022 Apr;256(4):388-401. doi: 10.1002/path.5849. Epub 2022 Feb 7. J Pathol. 2022. PMID: 34897700
MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma.
Kang EY, Millstein J, Popovic G, Meagher NS, Bolithon A, Talhouk A, Chiu DS, Anglesio MS, Leung B, Tang K, Lambie N, Pavanello M, Da-Anoy A, Lambrechts D, Loverix L, Olbrecht S, Bisinotto C, Garcia-Donas J, Ruiz-Llorente S, Yagüe-Fernandez M, Edwards RP, Elishaev E, Olawaiye A, Taylor S, Ataseven B, du Bois A, Harter P, Lester J, Høgdall CK, Armasu SM, Huang Y, Vierkant RA, Wang C, Winham SJ, Heublein S, Kommoss FKF, Cramer DW, Sasamoto N, van-Wagensveld L, Lycke M, Mateoiu C, Joseph J, Pike MC, Odunsi K, Tseng CC, Pearce CL, Bilic S, Conrads TP, Hartmann A, Hein A, Jones ME, Leung Y, Beckmann MW, Ruebner M, Schoemaker MJ, Terry KL, El-Bahrawy MA, Coulson P, Etter JL, LaVigne-Mager K, Andress J, Grube M, Fischer A, Neudeck N, Robertson G, Farrell R, Barlow E, Quinn C, Hettiaratchi A, Casablanca Y, Erber R, Stewart CJR, Tan A, Yu Y, Boros J, Brand AH, Harnett PR, Kennedy CJ, Nevins N, Morgan T, Fasching PA, Vergote I, Swerdlow AJ, Candido Dos Reis FJ, Maxwell GL, Neuhausen SL, Barquin-Garcia A, Modugno F, Moysich KB, Crowe PJ, Hirasawa A, Heitz F, Karlan BY, Goode EL, Sinn P, Horlings HM, Høgdall E, Sundfeldt K, Kommoss S, Staebler A, Wu AH, Cohen PA, DeFazio A, Lee CH, Steed H, Le ND, Gayther SA, Lawrenson K, Pharoah PDP, Konecny G, Cook LS, Ramus SJ, Kelemen LE, Köbel M. Kang EY, et al. Virchows Arch. 2022 Apr;480(4):855-871. doi: 10.1007/s00428-021-03232-0. Epub 2021 Nov 15. Virchows Arch. 2022. PMID: 34782936
Pan-cancer analysis identifies BIRC5 as a prognostic biomarker.
Fäldt Beding A, Larsson P, Helou K, Einbeigi Z, Parris TZ. Fäldt Beding A, et al. BMC Cancer. 2022 Mar 25;22(1):322. doi: 10.1186/s12885-022-09371-0. BMC Cancer. 2022. PMID: 35331169 Free PMC article.
Previous studies have shown that Survivin is abundant in most cancer cells, thereby making it a promising target for anti-cancer drugs and a potential prognostic tool. ...Survival data were analyzed with multivariable Cox proportional hazards regression analysis and …
Previous studies have shown that Survivin is abundant in most cancer cells, thereby making it a promising target for anti-cancer
Chemical constituents from Carica papaya Linn. leaves as potential cytotoxic, EGFRwt and aromatase (CYP19A) inhibitors; a study supported by molecular docking.
Hamed ANE, Abouelela ME, El Zowalaty AE, Badr MM, Abdelkader MSA. Hamed ANE, et al. RSC Adv. 2022 Mar 23;12(15):9154-9162. doi: 10.1039/d1ra07000b. eCollection 2022 Mar 21. RSC Adv. 2022. PMID: 35424860 Free PMC article.
The compounds 2, 3, 5-7 and 9 were isolated for the first time from the genus Carica. An in vitro breast cancer cytotoxicity study was evaluated with an MCF-7 cell line using the MTT assay. ...Clitorin showed the strongest interaction with aromatase (CYP19A1) for the breas …
The compounds 2, 3, 5-7 and 9 were isolated for the first time from the genus Carica. An in vitro breast cancer cytotoxicity study wa …
eIF6 rebinding dynamically couples ribosome maturation and translation.
Jaako P, Faille A, Tan S, Wong CC, Escudero-Urquijo N, Castro-Hartmann P, Wright P, Hilcenko C, Adams DJ, Warren AJ. Jaako P, et al. Nat Commun. 2022 Mar 23;13(1):1562. doi: 10.1038/s41467-022-29214-7. Nat Commun. 2022. PMID: 35322020 Free PMC article.
Antigen-Presenting B Cells Program the Efferent Lymph T Helper Cell Response.
Alsén S, Cervin J, Deng Y, Szeponik L, Wenzel UA, Karlsson J, Cucak H, Livingston M, Bryder D, Lu Q, Johansson-Lindbom B, Yrlid U. Alsén S, et al. Front Immunol. 2022 Mar 9;13:813203. doi: 10.3389/fimmu.2022.813203. eCollection 2022. Front Immunol. 2022. PMID: 35355990 Free PMC article.
Reduced immunogenicity of a third COVID-19 vaccination among recipients of allogeneic haematopoietic stem cell transplantation.
Einarsdottir S, Martner A, Nicklasson M, Wiktorin HG, Arabpour M, Törnell A, Vaht K, Waldenström J, Ringlander J, Bergström T, Brune M, Hellstrand K, Ljungman P, Lagging M. Einarsdottir S, et al. Haematologica. 2022 Mar 3. doi: 10.3324/haematol.2021.280494. Online ahead of print. Haematologica. 2022. PMID: 35236057 Free article.
Outcome of Ordinary Polymorphous Adenocarcinomas of the Salivary Glands in Comparison With Papillary and Cribriform Subtypes.
Clausen S, Falk M, Oesterling F, Fehr A, Stang A, Boecker W, Gesk S, Schatz S, Stenman G, Tiemann K, Loening T, Friedrich RE. Clausen S, et al. Anticancer Res. 2022 Mar;42(3):1455-1463. doi: 10.21873/anticanres.15616. Anticancer Res. 2022. PMID: 35220239
PATIENTS AND METHODS: A series of 155 PACs, including 10 PAPs and 12 CASGs from the population-based Cancer Registry of North Rhine-Westphalia (LKR-NRW) and the Hamburg Salivary Gland Reference Centre (HRC) were analyzed. ...
PATIENTS AND METHODS: A series of 155 PACs, including 10 PAPs and 12 CASGs from the population-based Cancer Registry of North Rhine-W …
Persistence of ctDNA in Patients with Breast Cancer During Neoadjuvant Treatment Is a Significant Predictor of Poor Tumor Response.
Zhou Q, Gampenrieder SP, Frantal S, Rinnerthaler G, Singer CF, Egle D, Pfeiler G, Bartsch R, Wette V, Pichler A, Petru E, Dubsky PC, Bago-Horvath Z, Fesl C, Rudas M, Ståhlberg A, Graf R, Weber S, Dandachi N, Filipits M, Gnant M, Balic M, Heitzer E. Zhou Q, et al. Clin Cancer Res. 2022 Feb 15;28(4):697-707. doi: 10.1158/1078-0432.CCR-21-3231. Clin Cancer Res. 2022. PMID: 34862246
EXPERIMENTAL DESIGN: We profiled 93 genes in tissue from 193 patients with early breast cancer. Patient-specific assays were designed for 145 patients to track ctDNA during NST in plasma. ctDNA presence and levels were correlated with complete pathological response (pCR) a …
EXPERIMENTAL DESIGN: We profiled 93 genes in tissue from 193 patients with early breast cancer. Patient-specific assays were designed …
FUS-DDIT3 Fusion Oncoprotein Expression Affects JAK-STAT Signaling in Myxoid Liposarcoma.
Dolatabadi S, Jonasson E, Andersson L, Luna Santamaría M, Lindén M, Österlund T, Åman P, Ståhlberg A. Dolatabadi S, et al. Front Oncol. 2022 Feb 3;12:816894. doi: 10.3389/fonc.2022.816894. eCollection 2022. Front Oncol. 2022. PMID: 35186752 Free PMC article.
Despite a generally favorable prognosis of myxoid liposarcoma, chemotherapy resistance remains a clinical problem. This cancer stem cell property is associated with JAK-STAT signaling, but the link to the myxoid-liposarcoma-specific FET fusion oncogene FUS-DDIT3 is not kno …
Despite a generally favorable prognosis of myxoid liposarcoma, chemotherapy resistance remains a clinical problem. This cancer stem c …
Sentinel lymph node localization and staging with a low-dose of superparamagnetic iron oxide (SPIO) enhanced MRI and magnetometer in patients with cutaneous melanoma of the extremity - The MAGMEN feasibility study.
Mirzaei N, Katsarelias D, Zaar P, Jalnefjord O, Johansson I, Leonhardt H, Wärnberg F, Olofsson Bagge R. Mirzaei N, et al. Eur J Surg Oncol. 2022 Feb;48(2):326-332. doi: 10.1016/j.ejso.2021.12.467. Epub 2022 Jan 1. Eur J Surg Oncol. 2022. PMID: 35000820 Free article.
A low dose of SPIO reduces the lymph node MRI artefacts, opening up for a non-invasive assessment of SLN status in patients with cancer....
A low dose of SPIO reduces the lymph node MRI artefacts, opening up for a non-invasive assessment of SLN status in patients with cancer
Clinical and biological relevance of the transcriptomic-based prostate cancer metastasis subtypes MetA-C.
Thysell E, Köhn L, Semenas J, Järemo H, Freyhult E, Lundholm M, Thellenberg Karlsson C, Damber JE, Widmark A, Crnalic S, Josefsson A, Welén K, Nilsson RJA, Bergh A, Wikström P. Thysell E, et al. Mol Oncol. 2022 Feb;16(4):846-859. doi: 10.1002/1878-0261.13158. Epub 2021 Dec 27. Mol Oncol. 2022. PMID: 34889043 Free PMC article.
To improve treatment of metastatic prostate cancer, the biology of metastases needs to be understood. We recently described three subtypes of prostate cancer bone metastases (MetA-C), based on differential gene expression. ...In conclusion, a distinct set of gene tr …
To improve treatment of metastatic prostate cancer, the biology of metastases needs to be understood. We recently described three sub …
Average duration of prior treatment lines predicts clinical benefit to eribulin chemotherapy in patients with metastatic breast cancer.
Coe F, Misra V, McCabe Y, Adderley H, Woodhouse L, Ayub Z, Wang X, Howell S, Ekholm M. Coe F, et al. Breast Cancer Res Treat. 2022 Feb;191(3):535-543. doi: 10.1007/s10549-021-06438-7. Epub 2021 Nov 29. Breast Cancer Res Treat. 2022. PMID: 34843027 Free PMC article.
PURPOSE: The aim of this study was to identify factors associated with progression-free survival (PFS) and overall survival (OS) in patients with metastatic breast cancer (MBC) treated with eribulin in a real-world setting, to improve information provision in those conside …
PURPOSE: The aim of this study was to identify factors associated with progression-free survival (PFS) and overall survival (OS) in patients …
Tissue architecture delineates field cancerization in BRAFV600E-induced tumor development.
Schoultz E, Johansson E, Moccia C, Jakubikova I, Ravi N, Liang S, Carlsson T, Montelius M, Patyra K, Kero J, Paulsson K, Fagman H, Bergo MO, Nilsson M. Schoultz E, et al. Dis Model Mech. 2022 Feb 1;15(2):dmm048887. doi: 10.1242/dmm.048887. Epub 2021 Aug 11. Dis Model Mech. 2022. PMID: 34379110 Free PMC article.
Cancer cells hijack developmental growth mechanisms but whether tissue morphogenesis and architecture modify tumorigenesis is unknown. ...Female mice developed larger tumors than males, reproducing the gender difference of human thyroid cancer. These data indicate t
Cancer cells hijack developmental growth mechanisms but whether tissue morphogenesis and architecture modify tumorigenesis is unknown
Characterization of surface markers on extracellular vesicles isolated from lymphatic exudate from patients with breast cancer.
Ekström K, Crescitelli R, Pétursson HI, Johansson J, Lässer C, Olofsson Bagge R. Ekström K, et al. BMC Cancer. 2022 Jan 10;22(1):50. doi: 10.1186/s12885-021-08870-w. BMC Cancer. 2022. PMID: 35012489 Free PMC article.
BACKGROUND: Breast cancer is the most common cancer, and the leading cause of cancer-related deaths, among females world-wide. Recent research suggests that extracellular vesicles (EVs) play a major role in the development of breast cancer metas …
BACKGROUND: Breast cancer is the most common cancer, and the leading cause of cancer-related deaths, among females worl …
Integration of spatial and single-cell transcriptomic data elucidates mouse organogenesis.
Lohoff T, Ghazanfar S, Missarova A, Koulena N, Pierson N, Griffiths JA, Bardot ES, Eng CL, Tyser RCV, Argelaguet R, Guibentif C, Srinivas S, Briscoe J, Simons BD, Hadjantonakis AK, Göttgens B, Reik W, Nichols J, Cai L, Marioni JC. Lohoff T, et al. Nat Biotechnol. 2022 Jan;40(1):74-85. doi: 10.1038/s41587-021-01006-2. Epub 2021 Sep 6. Nat Biotechnol. 2022. PMID: 34489600 Free PMC article.
The Proteomic Signature of Intestinal Acute Rejection in the Mouse.
Oltean M, Bagge J, Dindelegan G, Kenny D, Molinaro A, Hellström M, Nilsson O, Sihlbom C, Casselbrant A, Davila M, Olausson M. Oltean M, et al. Metabolites. 2021 Dec 27;12(1):23. doi: 10.3390/metabo12010023. Metabolites. 2021. PMID: 35050145 Free PMC article.
100 results